EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study

Anna Panovská, Pavel Žák iD, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3280 ↗

At a glance

Journal article in Hematological Oncology, 2024. Written by Anna Panovská and 9 co-authors. Institution: Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic. Major MEDLINE topics: Leukemia, Hairy Cell. Cited 4 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: EARTRIS-CZ, National Institute for Cancer Research (Program EXCELES), Czech CLL Study Group.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Hairy cell leukemia (HCL) and HCL‐like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real‐world setting. We analyzed 225 HCL and 26 HCLv patients with median follow‐up of 67.9 months (HCL) and 20.1 months (HCLv). Median age at diagnosis was 56.2 (HCL) and 69.5 years (HCLv), male predominance was observed in both groups (76.0% vs. 73.1%). Diagnostics was mostly based on morphological evidence of hairy cells in the peripheral blood and bone marrow. At diagnosis, BRAF V6 00E mutation was detected in 94.7% of examined HCL patients and in no HCLv patient. Front‐line treatment was indicated in 205 (91.1%) HCL and 18 (69.2%) HCLv patients. The majority of HCL patients were administered a cladribine‐based regimen (91.2%). Overall response rate (ORR) was higher in cladribine‐treated patients compared to those given other treatments (97.7% vs. 81.3%), the same applied with achieving Complete remission (CR) (91.2% vs. 62.5%). HCLv treatment was heterogeneous, but cladribine remained the most frequent option (44.4%) with ORR 81.3% and CR rates 43.8%. Second‐line treatment was indicated in 52 HCL and 8 HCLv patients, 25.4% and 44.4% of those treated in first‐line. In the whole HCL group, median time to next treatment (TTNT) was not reached and 10‐year TTNT was estimated at 74.1%. HCLv patients who underwent first‐line treatment had a median TTNT of 56 months. The median overall survival (OS) in HCL patients was not reached compared to HCLv with a median OS of 9.5 years. These data confirm an excellent prognosis for HCL patients treated with cladribine‐based therapy. On the contrary, HCLv with its aggressive behavior represents a group of patients in whom novel treatment approaches are needed.

Subjects

MeSH terms (MEDLINE)

Leukemia, Hairy CellHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAdultAged, 80 and overTreatment OutcomeCladribineFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins B-raf

Author keywords

BRAF V600Emutationcladribinehairy cell leukemiahairy cell leukemia variantoverall survivaltime to next treatment

Substances

CladribineProto-Oncogene Proteins B-raf

Authors and institutions

  • Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

ORCID profiles: Pavel Žák, Michael Doubek

Funding

  • EARTRIS-CZ
  • National Institute for Cancer Research (Program EXCELES)
  • Czech CLL Study Group

Cite

APA

Panovská, A., Žák, P., Jurková, T., Arpáš, T., Brychtová, Y., Vašíková, A., Hrabčáková, V., Prchlíková, A., Filipová, M., & Doubek, M. (2024). Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study. Hematological Oncology. https://doi.org/10.1002/hon.3280

Vancouver

Panovská A, Žák P, Jurková T, Arpáš T, Brychtová Y, Vašíková A, et al. Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study. Hematological Oncology. 2024. doi:10.1002/hon.3280

BibTeX
@article{Panovsk2024,
  author = {Panovská, Anna and Žák, Pavel and Jurková, Tereza and Arpáš, Tomáš and Brychtová, Yvona and Vašíková, Alžběta and Hrabčáková, Viera and Prchlíková, Adéla and Filipová, Martina and Doubek, Michael},
  title = {Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3280}
}
Start for free →